1/12
04:01 pm
vstm
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/30
03:38 pm
vstm
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC [Seeking Alpha]
Neutral
Report
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC [Seeking Alpha]
12/30
07:17 am
vstm
Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/29
04:01 pm
vstm
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Medium
Report
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
12/15
04:45 pm
vstm
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth [Yahoo! Finance]
Medium
Report
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth [Yahoo! Finance]
12/15
04:01 pm
vstm
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
Medium
Report
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
12/15
09:43 am
vstm
Verastem, Inc. (NASDAQ:VSTM) is favoured by institutional owners who hold 60% of the company [Yahoo! Finance]
Medium
Report
Verastem, Inc. (NASDAQ:VSTM) is favoured by institutional owners who hold 60% of the company [Yahoo! Finance]
11/25
07:30 am
vstm
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
Medium
Report
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
11/20
06:03 am
vstm
Verastem (NASDAQ:VSTM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Verastem (NASDAQ:VSTM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/14
12:41 am
vstm
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
11/5
07:30 am
vstm
Verastem Oncology to Present at Upcoming Investor Conferences
Low
Report
Verastem Oncology to Present at Upcoming Investor Conferences
11/4
10:22 am
vstm
Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/4
07:30 am
vstm
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
High
Report
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates